文献速递艾滋病与性传播感染

换用多替拉韦/拉米夫定与维持三联方案对HIV细胞DNA水平影响的对照研究

Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

结果显示两组HIV DNA下降幅度相当,换用双药对细胞储库大小的影响不劣于三联方案。

要点

  • 换用多替拉韦/拉米夫定后48周HIV DNA下降幅度与三联方案相当。
  • 两组HIV DNA基线水平及48周变化无显著差异。
  • 基线CD4/CD8比值较高者HIV DNA下降更明显。

核心结论

  • 多替拉韦/拉米夫定维持治疗48周对HIV DNA水平的影响与三联方案相同。

研究设计与样本

  • 前瞻性、纵向、匹配对照研究,纳入40例换用多替拉韦/拉米夫定(DT组)和40例维持三联方案(TT组)的病毒学抑制患者,按年龄、性别、HIV诊断年限、ART年限和锚定药物1:1匹配。

主要发现

  • 基线HIV DNA水平DT组为2.27(IQR 1.97-2.47)log10 copies/10^6白细胞,TT组为2.26(IQR 2.05-2.61),两组相当。
  • 第48周HIV DNA变化DT组为-0.105(IQR -0.384至0.121,P=0.041),TT组为-0.132(IQR -0.362至0.046,P=0.005),组间下降幅度可比(P=0.821)。
  • 较高的HIV DNA下降与较高的基线CD4/CD8比值相关。

临床怎么用

  • 对于病毒学抑制的HIV感染者,换用多替拉韦/拉米夫定双药维持治疗不增加细胞储库负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of switching to dolutegravir plus lamivudine maintenance therapy on the HIV cellular reservoir size. PATIENTS AND METHODS: This was a prospective, longitudinal, matched, controlled study. We enrolled virologically suppressed patients on stable three-drug ART who switched at baseline (BL) to dolutegravir/lamivudine (DT group) or maintained triple therapy (TT group); subjects in the TT group were matched 1:1 with those in the DT group according to age, gender, years since HIV diagnosis, years on ART and anchor drug. Total blood-associated HIV DNA levels were assessed by droplet digital PCR at BL and after 48 weeks (T48). Results were expressed as log10 HIV DNA copies/106 leucocytes. RESULTS: We enrolled 40 patients in the DT group and 40 in the TT group; the two groups were homogeneous for all main characteristics except nadir CD4 cell count. At BL, HIV DNA levels were comparable between the DT and TT groups: 2.27 (IQR 1.97-2.47) and 2.26 (IQR 2.05-2.61) log10 HIV DNA copies/106 leucocytes, respectively. Change in HIV DNA load from BL to T48 was -0.105 (IQR -0.384 to 0.121, P = 0.041) in the DT group and -0.132 (IQR -0.362 to 0.046, P = 0.005) in the TT group, with a comparable decline observed between the two groups (P = 0.821). A higher HIV DNA decline was associated with higher BL CD4/CD8 ratio. CONCLUSIONS: Maintenance therapy with dolutegravir/lamivudine had the same impact as the triple regimen on HIV DNA levels after 48 weeks of treatment. These data seem to support the effectiveness of a dolutegravir/lamivudine dual regimen in controlling the magnitude of the cellular reservoir (www.clinicaltrials.gov, number NCT02836782).

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lombardi F, Belmonti S, Borghetti A, et al. Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. J Antimicrob Chemother. 2020. PMID: 32101614. doi:10.1093/jac/dkaa058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。